Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference: A Look into the Future of RAS(ON) Inhibitors

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers, has announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. PT. The presentation will provide an update on the company's pipeline, clinical progress, and strategic initiatives, offering investors and industry professionals a glimpse into the future of Revolution Medicines' RAS(ON) inhibitors.

Revolution Medicines' RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805, have demonstrated promising clinical results in various RAS-mutant cancer types, such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer. The company's pipeline also includes other RAS(ON) mutant-selective inhibitors and RAS companion inhibitors, which are being explored in combination treatment strategies.

In the upcoming presentation, Revolution Medicines is expected to provide updates on its ongoing clinical trials, such as the Phase 3 RASolute 302 study of RMC-6236 in previously treated metastatic PDAC and the Phase 1/1b study of RMC-6236 in non-small cell lung cancer. The company may also share new data from its combination studies, including those evaluating RMC-6236 with pembrolizumab, RMC-6291 with pembrolizumab, and the first-of-its-kind RAS(ON) inhibitor doublet combination of RMC-6291 and RMC-6236.

Revolution Medicines' presentation at the 43rd Annual J.P. Morgan Healthcare Conference is an opportunity for investors to gain insights into the company's progress, pipeline, and strategic initiatives. The presentation will likely highlight the company's competitive advantages, such as its targeted therapies for RAS-addicted cancers, RAS(ON) inhibitors, and innovative combination treatment strategies. By attending the presentation, investors can make informed decisions about the potential of Revolution Medicines' RAS(ON) inhibitors in the rapidly evolving precision oncology landscape.